ArticleFrontiers in public health2025
Global, regional, and national burden of older adult atopic dermatitis in 204 countries and territories worldwide.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Efficacy and Safety of Subcutaneous Rocatinlimab in Adults With Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomised Placebo-Controlled Trials.Dermatology research and practice · 2026Review
- The Neuroimmune Axis in Atopic Dermatitis: From Pathogenic Mechanisms to Targeted Neuroimmunotherapy.Journal of inflammation research · 2025Review
- Global burden, inequality, and frontier gaps of autism spectrum disorder disability in adolescents and young adults, 1990-2021: a systematic analysis of the GBD 2021 study.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With the aging global population, older adult atopic dermatitis (AD) is emerging as an increasingly significant health challenge. This study aimed to evaluate the global burden of older adult AD from 1990 to 2021 and to project its change to 2050. Methods: The estimates and 95% uncertainty intervals of prevalence, incidence, and disability-adjusted life-years (DALYs) attributable to AD among individuals aged over 60 years were extracted from the Global Burden of Diseases (GBD) Study 2021. We used joinpoint regression analysis, decomposition analysis, cross-country inequality analysis, frontier analysis and prediction model to epidemiological analysis. Results: From 1990 to 2021, the global prevalence of older adult AD increased to 11,009,630 cases (95% UI: 9,915,829 to 12,170,941), even as ASRs declined, which were primarily driven by population growth. It was observed that females and 75-79 years old had higher incidence rates. SDI relative and frontier analysis exhibited that incidence, prevalence and DALYs rates were positively correlated with SDI levels, while SDI-related inequalities had a significant decrease. Predictions up to 2050 anticipated increasing older adult AD incidence, prevalence, and DALYs numbers, while only age-standardized disability-adjusted life-year rates (ASDRs) were expected to decline. Conclusion: The burden of older adult AD varied by genders, age groups, regions, countries and climatic conditions. Although the ASRs had shown a decline over time, the burden of older adult AD remained significant, especially in regions with high SDI levels. In the future, the burden of older adult AD was projected to continue rising until 2050, thereby targeted interventions and public health strategies were needed to address this trend.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.